Patents by Inventor Patrick Daugherty
Patrick Daugherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210284721Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: October 22, 2020Publication date: September 16, 2021Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10875913Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: August 23, 2018Date of Patent: December 29, 2020Assignee: CytomX Therapeutics, Inc.Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20190119370Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: August 23, 2018Publication date: April 25, 2019Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10118961Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: August 24, 2016Date of Patent: November 6, 2018Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 10059762Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: April 28, 2016Date of Patent: August 28, 2018Assignee: CytomX Therapeutics, Inc.Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20170081397Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: August 24, 2016Publication date: March 23, 2017Inventors: Nancy E. Stagliano, James William West, Kathryn Kamath, Paul Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Patent number: 9453078Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: September 26, 2013Date of Patent: September 27, 2016Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20160228546Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: April 28, 2016Publication date: August 11, 2016Inventors: Nancy Elizabeth Stagliano, James William West, Kathryn Kamath, Paul Henry Bessette, Fred Gluck, Jason Gary Sagert, Patrick Daugherty
-
Publication number: 20140024810Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: September 26, 2013Publication date: January 23, 2014Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20130309230Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: March 4, 2013Publication date: November 21, 2013Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8563269Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: December 9, 2011Date of Patent: October 22, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
-
Patent number: 8518404Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: GrantFiled: March 2, 2012Date of Patent: August 27, 2013Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
-
Patent number: 8513390Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: April 25, 2012Date of Patent: August 20, 2013Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20120244154Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: ApplicationFiled: March 2, 2012Publication date: September 27, 2012Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
-
Publication number: 20120237977Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: ApplicationFiled: March 2, 2012Publication date: September 20, 2012Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
-
Publication number: 20120207756Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: April 25, 2012Publication date: August 16, 2012Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick W. Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20100189651Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: ApplicationFiled: January 12, 2010Publication date: July 29, 2010Applicant: CytomX Therapeutics, LLCInventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Frederick Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20090304719Abstract: The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.Type: ApplicationFiled: August 21, 2008Publication date: December 10, 2009Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
-
Publication number: 20070258954Abstract: The invention relates to methods of selecting proteins, out of large libraries, having desirable characteristics. Exemplified are methods of expressing enzymes and antibodies on the surface of host cells and selecting for desired activities. These methods have the advantage of speed and ease of operation when compared with current methods. They also provide, without additional cloning, a source of significant quantities of the protein of interest.Type: ApplicationFiled: December 22, 2005Publication date: November 8, 2007Inventors: Brent Iverson, George Georgiou, Gang Chen, Mark Olsen, Patrick Daugherty
-
Publication number: 20070099247Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: ApplicationFiled: December 19, 2006Publication date: May 3, 2007Inventors: Patrick Daugherty, Paul Bessette, Jeffrey Rice